Informa Markets Korea has officially opened pre-registration for CPHI/ Hi Korea 2026, set to take place at COEX in Seoul from August 25 to 27. Pre-registered visitors receive complimentary entry to the event, which is the Korea edition of the global CPHI series.
Largest Edition Yet with Expanded Space and International Participation
This year marks the largest edition to date, expanding across COEX Halls C, E and The Platz. The exhibition space has increased by approximately 14% year-on-year. Around 420 companies from over 70 countries will showcase their latest ingredients, products and technology solutions to an estimated 12,000 or more industry professionals.
As a key meeting point for pharma, bio, and nutraceutical players worldwide, the show facilitates global networking, strengthens domestic partnerships among Korean companies, and encourages cross-border collaborations. Korea's leading pharma manufacturing, advanced CDMO infrastructure, and fast-growing nutraceutical market underpin the event's strategic role for business across Asia and beyond.
Major Sponsors and Government Support
Major government and industry organizations have stepped forward as sponsors. These include the Ministry of Food and Drug Safety (MFDS), Korea Fund for Regenerative Medicine (KFRM), Korea Institute of Toxicology (KIT), Korea Health Functional Food Association (KHFF), Korea Drug Research Association (KDRA), Korea Invention Promotion Association (KIPA), and DIPS. The Bio Zone is co-organized with the Korea Biomedicine Industry Association (KoBIA).
Expanded Seminar and Conference Program
Reflecting strong industry interest, the conference program expands from 4 tracks in 2025 to 6 tracks in 2026, offering broader coverage. Following last year's success, the K-Health Conference will include MFDS-led discussions on personalized health functional food regulations.
On the bio and pharma side, dedicated sessions will spotlight Korea's emerging K-platform technologies, including antibody-drug conjugates (ADC), targeted protein degradation (TPD), and radiopharmaceutical therapy (RPT), as well as clinical trials and the latest GLP-1-related developments. The program also features the Biohealth Policy Forum hosted by KDRA, providing insights into industry policy direction and strategic priorities.
The conference includes investor relations (IR) sessions, a Startup Challenge, and the Global Build-Up Program, supporting commercialization and market entry across Japan, China, Thailand, Malaysia, and the United States.
Hall E Nearing Sell-Out: Final Booth Applications
Hall E, secured to accommodate overflow demand, is also nearing full capacity. Companies considering participation are encouraged to apply early. Pre-registration is available at the official CPHI Korea website.
This content is sourced from a syndicated feed and is published as received. The Tribune assumes no responsibility or liability for its accuracy, completeness, or content.
